ArticleContrast media & molecular imaging
Nature-inspired nanoformulations for contrast-enhanced in vivo MR imaging of macrophages.
Article in Contrast media & molecular imaging. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 27 citations in OpenAlex.
- A New Function of the S100-A4 Protein (Mts1): Mts1 Stimulates the Activation of Cytotoxic Lymphocytes via the TREM-1 Receptor.International journal of molecular sciences · 2026Article
- Artificial recombinant high-density protein nanocarriers for precision drug delivery.Chemical science · 2026Review
- TREM-1 inhibitor specificity and timing of treatment initiation can impact its therapeutic efficacy in cancer and inflammatory disease.Frontiers in oncology · 2025Article
- Inhibition of TREM-2 Markedly Suppresses Joint Inflammation and Damage in Experimental Arthritis.International journal of molecular sciences · 2022Article
- Nanoparticles in the diagnosis and treatment of vascular aging and related diseases.Signal transduction and targeted therapy · 2022Review
- Nanoparticle theranostics in cardiovascular inflammation.Seminars in immunology · 2021Review
- Molecular and Nonmolecular Imaging of Macrophages in Atherosclerosis.Frontiers in cardiovascular medicine · 2021Review
- Understanding the Exchange of Systemic HDL Particles Into the Brain and Vascular Cells Has Diagnostic and Therapeutic Implications for Neurodegenerative Diseases.Frontiers in physiology · 2021Review
- SCHOOL of nature: ligand-independent immunomodulatory peptides.Drug discovery today · 2020Article
- High density lipoprotein mimicking nanoparticles for atherosclerosis.Nano convergence · 2020Review
- Biomimetic nanoparticle technology for cardiovascular disease detection and treatment.Nanoscale horizons · 2020Review
- Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research.Molecules (Basel, Switzerland) · 2019Review
- Inhibition of Triggering Receptor Expressed on Myeloid Cells 1 Ameliorates Inflammation and Macrophage and Neutrophil Activation in Alcoholic Liver Disease in Mice.Hepatology communications · 2019Article
- Blockade of TREM-1 prevents vitreoretinal neovascularization in mice with oxygen-induced retinopathy.Biochimica et biophysica acta. Molecular basis of disease · 2018Article
- Reconstituted high-density lipoproteins: novel biomimetic nanocarriers for drug delivery.Acta pharmaceutica Sinica. B · 2018Review
- Novel TREM-1 Inhibitors Attenuate Tumor Growth and Prolong Survival in Experimental Pancreatic Cancer.Molecular pharmaceutics · 2017Article
- Rationally designed ligand-independent peptide inhibitors of TREM-1 ameliorate collagen-induced arthritis.Journal of cellular and molecular medicine · 2017Article
- Detection and treatment of atherosclerosis using nanoparticles.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017Review
- Lipoproteins and lipoprotein mimetics for imaging and drug delivery.Advanced drug delivery reviews · 2016Review
- SARS Coronavirus Fusion Peptide-Derived Sequence Suppresses Collagen-Induced Arthritis in DBA/1J Mice.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Magnetic resonance imaging (MRI) of macrophages in atherosclerosis requires the use of contrast-enhancing agents. Reconstituted lipoprotein particles that mimic native high-density lipoproteins (HDL) are a versatile delivery platform for Gd-based contrast agents (GBCA) but require targeting moieties to direct the particles to macrophages. In this study, a naturally occurring methionine oxidation in the major HDL protein, apolipoprotein (apo) A-I, was exploited as a novel way to target HDL to macrophages. We also tested if fully functional GBCA-HDL can be generated using synthetic apo A-I peptides. The fluorescence and MRI studies reveal that specific oxidation of apo A-I or its peptides increases the in vitro macrophage uptake of GBCA-HDL by 2-3 times. The in vivo imaging studies using an apo E-deficient mouse model of atherosclerosis and a 3.0 T MRI system demonstrate that this modification significantly improves atherosclerotic plaque detection using GBCA-HDL. At 24 h post-injection of 0.05 mmol Gd kg(-1) GBCA-HDL containing oxidized apo A-I or its peptides, the atherosclerotic wall/muscle normalized enhancement ratios were 90 and 120%, respectively, while those of GBCA-HDL containing their unmodified counterparts were 35 and 45%, respectively. Confocal fluorescence microscopy confirms the accumulation of GBCA-HDL containing oxidized apo A-I or its peptides in intraplaque macrophages. Together, the results of this study confirm the hypothesis that specific oxidation of apo A-I targets GBCA-HDL to macrophages in vitro and in vivo. Furthermore, our observation that synthetic peptides can functionally replace the native apo A-I protein in HDL further encourages the development of these contrast agents for macrophage imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.